Spain - Spanish - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fresenius kabi espaÑa, s.a.u. - sodio cloruro; cloruro de potasio - soluciÓn para perfusiÓn - 0,9% + 20 meq/1.000 ml inyectable - sodio cloruro 9 mg; cloruro de potasio 0,02 meq - electrolitos

Spain - Spanish - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fresenius kabi espaÑa, s.a.u. - sodio cloruro; cloruro de potasio - soluciÓn para perfusiÓn - 0,9% + 40 meq/1.000 ml inyectable - sodio cloruro 9 mg; cloruro de potasio 0,04 meq - electrolitos

European Union - Spanish - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - pegfilgrastim - neutropenia - inmunoestimulantes, , factores estimulantes de colonias - reducción en la duración de la neutropenia y la incidencia de neutropenia febril en pacientes adultos tratados con quimioterapia citotóxica para la malignidad (con la excepción de crónica mieloide leucemia y mielodisplásicos síndromes).

Ecuador - Spanish - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh [de] germany - poligelina 3.5 g - solucion inyectable - cada 100 ml contiene: poligelina 3.5000 g (equivalente a 0.630 g de nitrógeno) cloruro de sodio 0.8500 g cloruro de potasio 0.0380 g cloruro de calcio dihidratado 0.0927 g

European Union - Spanish - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - inmunosupresores - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Ecuador - Spanish - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh alemania - 4 mg - solucion concentrada para infusion - cada 5 ml contiene: acido zoledronico monohidrato 4.265 mg

Ecuador - Spanish - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh alemania - paracetamol 10 mg - solucion para infusion - cada ml contiene: paracetamol 10 mg

Ecuador - Spanish - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

fresenius kabi deutschland gmbh alemania - l-isoleucina 10,40 g l-leucina 13,09 g l-lysina monoacetato correspondiente l-lisina 6,88 g l-metionina 1,10 g n-acetil-l-cisteina correspondiente a l-cisteina 0,52 g l-fenilalanina 0,88 g l-treonina 4,40 g l-triptofano 0,70 g l-valina 10,08 g l-arginina 10,72 g l-histidina - solucion para infusion - cada ml solución de infusión contienen: l-isoleucina 10,40 mg l-leucina 13,09 mg l-lysina monoacetato 9,71 mg correspondiente l-lisina 6,88 mg l-metionina 1,10 mg n-acetil-l-cisteina 0,77 mg correspondiente a l-lisina 0,52 mg l-fenilalanina 0,88 mg l-treonina 4,40 mg l-triptofano 0,70 mg l-valina 10,08 mg l-arginina 10,72 mg l-histidina 2,80 mg acido aminoacético (glicina) 5,82 mg l-alanina 4,64 mg l-prolina 5,73 mg l-serina 2,24 mg

Spain - Spanish - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fresenius kabi espaÑa, s.a.u. - citarabina - soluciÓn inyectable y para perfusiÓn - 100 mg inyectable 20 ml - citarabina 100 mg - citarabina

Spain - Spanish - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

fresenius kabi españa, s.a.u. - cisatracurio besilato - excipientes: n/a - agentes relajantes musculares de acciÓn perifÉrica - otros compuestos de amonio cuaternario - cisatracurio, besilato de